H. Weclawiak, C. Mengelle, O. Mohamed, A. Izopet, J. Rostaing et al., Effets du cytom??galovirus en transplantation et place de la prophylaxie antivirale, N??phrologie & Th??rapeutique, vol.6, issue.6, pp.505-512, 2010.
DOI : 10.1016/j.nephro.2010.06.003

R. Rubin, The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the ???silo hypothesis???, Current Opinion in Infectious Diseases, vol.20, issue.4, pp.399-407, 2007.
DOI : 10.1097/QCO.0b013e328285a358

A. Limaye, G. Raghu, D. Koelle, J. Ferrenberg, M. Huang et al., High Incidence of Ganciclovir???Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy, The Journal of Infectious Diseases, vol.185, issue.1, pp.20-27, 2002.
DOI : 10.1086/338143

I. Sia and R. Patel, New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients, Clinical Microbiology Reviews, vol.13, issue.1, pp.83-121, 2000.
DOI : 10.1128/CMR.13.1.83-121.2000

J. Fishman and R. Rubin, Infection in organ-transplant recipie n t s . N E n g l J M e, 1998.

T. Bailey, R. Buller, N. Ettinger, E. Trulock, M. Gaudreault-keener et al., Quantitative Analysis of Cytomegalovirus Viremia in Lung Transplant Recipients, Journal of Infectious Diseases, vol.171, issue.4, pp.1006-1010, 1995.
DOI : 10.1093/infdis/171.4.1006

H. Schaeffer, Acyclovir chemistry and spectrum of activity, The American Journal of Medicine, vol.73, issue.1, pp.4-6, 1982.
DOI : 10.1016/0002-9343(82)90054-7

J. Martin, C. Dvorak, D. Smee, T. Matthews, and J. Verheyden, ,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent, J Med Chem, vol.91, issue.26, pp.759-761, 1983.

V. Sullivan, C. Talarico, S. Stanat, M. Davis, D. Coen et al., A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells, Nature, vol.358, issue.6382, 1992.
DOI : 10.1038/358162a0

E. Littler, A. Stuart, and M. Chee, Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir, Nature, vol.358, issue.6382, pp.160-162, 1992.
DOI : 10.1038/358160a0

K. Biron, S. Stanat, J. Sorrell, J. Fyfe, P. Keller et al., Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus., Proceedings of the National Academy of Sciences, vol.82, issue.8, pp.2473-2477, 1985.
DOI : 10.1073/pnas.82.8.2473

S. Flechner, R. Avery, R. Fisher, B. Mastroianni, D. Papajcik et al., A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients, Transplantation, vol.66, pp.3053-3055, 1998.

D. Winston, D. Wirin, A. Shaked, and R. Busuttil, Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients, The Lancet, vol.346, issue.8967, pp.69-74, 1995.
DOI : 10.1016/S0140-6736(95)92110-9

H. Weclawiak, C. Mengelle, O. Mohamed, A. Izopet, J. Rostaing et al., Effets du cytom??galovirus en transplantation et place de la prophylaxie antivirale, N??phrologie & Th??rapeutique, vol.6, issue.6, pp.505-512, 2010.
DOI : 10.1016/j.nephro.2010.06.003

S. Bataille, V. Moal, J. Gaudart, M. Indreies, R. Purgus et al., Cytomegalovirus risk factors in renal transplantation with modern immunosuppression, Transplant Infectious Disease, vol.55, issue.(4, pp.480-488, 2010.
DOI : 10.1111/j.1399-3062.2010.00533.x

D. Clercq and E. , Antivirals and antiviral strategies, Nature Reviews Microbiology, vol.62, issue.9, pp.704-720, 2004.
DOI : 10.1073/pnas.2234683100

H. Wiltshire, C. Paya, M. Pescovitz, A. Humar, E. Dominguez et al., Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients, Transplantation, vol.79, issue.11, pp.1477-1483, 2005.
DOI : 10.1097/01.TP.0000164512.99703.AD

M. Jordan, Latent Infection and the Elusive Cytomegalovirus, Clinical Infectious Diseases, vol.5, issue.2, pp.205-215, 1983.
DOI : 10.1093/clinids/5.2.205

R. Diamond, R. Keller, G. Lee, and D. Finkel, Lysis of Cytomegalovirus-lnfected Human Fibroblasts and Transformed Human Cells by Peripheral Blood Lymphoid Cells from Normal Human Donors, Experimental Biology and Medicine, vol.154, issue.2, pp.259-263, 1977.
DOI : 10.3181/00379727-154-39650

H. Riley, History of the Cytomegalovirus, Southern Medical Journal, vol.90, issue.2, pp.184-190, 1997.
DOI : 10.1097/00007611-199702000-00004

A. Bankier, S. Beck, R. Bohni, C. Brown, R. Cerny et al., The DNA sequence of the human cytomegalovirus genome, DNA Sequence, vol.1, issue.1, pp.1-12, 1991.
DOI : 10.1016/0042-6822(90)90294-2

M. Chee, A. Bankier, S. Beck, R. Bohni, C. Brown et al., Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169, Curr Top Microbiol Immunol, vol.154, pp.125-169, 1990.
DOI : 10.1007/978-3-642-74980-3_6

W. Rowe, J. Hartley, S. Waterman, H. Turner, and R. Huebner, Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids, Proc Soc Exp Biol Med Soc Exp Biol Med N Y N, vol.92, pp.418-424, 1956.

A. Dolan, C. Cunningham, R. Hector, A. Hassan-walker, L. Lee et al., Genetic content of wild-type human cytomegalovirus, Journal of General Virology, vol.85, issue.5, pp.1301-1312, 2004.
DOI : 10.1099/vir.0.79888-0

S. Sijmons, M. Van-ranst, and P. Maes, Genomic and Functional Characteristics of Human Cytomegalovirus Revealed by Next-Generation Sequencing, Viruses, vol.6, issue.3, pp.1049-1072, 2014.
DOI : 10.3390/v6031049

E. Littler, A. Stuart, and M. Chee, Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir, Nature, vol.358, issue.6382, pp.160-162, 1992.
DOI : 10.1038/358160a0

M. E. Jr, A. Arvin, G. Campadelli-fiume, E. Mocarski, . Moore et al., Betaherpes viral genes and their functions, Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, 2007.

M. Lopper and T. Compton, Coiled-Coil Domains in Glycoproteins B and H Are Involved in Human Cytomegalovirus Membrane Fusion, Journal of Virology, vol.78, issue.15, pp.8333-8341, 2004.
DOI : 10.1128/JVI.78.15.8333-8341.2004

K. Döhner and B. Sodeik, The Role of the Cytoskeleton During Viral Infection, Curr Top Microbiol Immunol, vol.285, pp.67-108, 2005.
DOI : 10.1007/3-540-26764-6_3

L. Wiebusch, J. Asmar, R. Uecker, and C. Hagemeier, Human cytomegalovirus immediate-early over protein 2 (IE2)-mediated activation of cyclin E is cell-cycle-independent and forces S-phase entry in IE2-arrested cells, Journal of General Virology, vol.84, issue.1, pp.51-60, 2003.
DOI : 10.1099/vir.0.18702-0

C. Paulus, S. Krauss, and M. Nevels, A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling, Proceedings of the National Academy of Sciences, vol.103, issue.10, pp.3840-3845, 2006.
DOI : 10.1073/pnas.0600007103

X. Yu, P. Trang, S. Shah, I. Atanasov, Y. Kim et al., Dissecting human cytomegalovirus gene function and capsid maturation by ribozyme targeting and electron cryomicroscopy, Proceedings of the National Academy of Sciences, vol.102, issue.20, pp.7103-7111, 2005.
DOI : 10.1073/pnas.0408826102

T. Mettenleiter, B. Klupp, and H. Granzow, Herpesvirus assembly: An update, Virus Research, vol.143, issue.2, pp.222-256, 2009.
DOI : 10.1016/j.virusres.2009.03.018

M. Kumar, G. Nankervis, and E. Gold, Inapparent Congenital Cytomegalovirus Infection, New England Journal of Medicine, vol.288, issue.26, pp.1370-1372, 1973.
DOI : 10.1056/NEJM197306282882603

E. Gold and G. Nankervis, Cytomegalovirus Viral infections of humans: epidemiology and control, pp.143-161, 1976.

S. Stagno, R. Pass, G. Cloud, W. Britt, R. Henderson et al., Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome, JAMA: The Journal of the American Medical Association, vol.256, issue.14, pp.1904-1912, 1986.
DOI : 10.1001/jama.256.14.1904

P. Griffiths, C. Baboonian, D. Rutter, and C. Peckham, Congenital and maternal cytomegalovirus infections in a London population, BJOG: An International Journal of Obstetrics and Gynaecology, vol.158, issue.2, pp.135-140, 1991.
DOI : 10.1001/jama.256.14.1904

A. Casteels, A. Naessens, F. Gordts, D. Catte, L. Bougatef et al., Neonatal screening for congenital cytomegalovirus infections, Journal of Perinatal Medicine, vol.27, issue.2, pp.116-121, 1999.
DOI : 10.1515/JPM.1999.015

M. Barbi, S. Binda, V. Primache, and D. Clerici, Congenital cytomegalovirus infection in a northern Italian region. NEOCMV Group, European Journal of Epidemiology, vol.14, issue.8, pp.791-796, 1998.
DOI : 10.1023/A:1007554726449

W. Williamson, G. Demmler, A. Percy, and F. Catlin, Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection, Pediatrics, vol.90, pp.862-866, 1992.

H. Smithers-sheedy, C. Raynes-greenow, N. Badawi, G. Khandaker, R. Menzies et al., Cytomegalovirus-related childhood mortality in Australia, 1999.

A. Rowshani, F. Bemelman, E. Van-leeuwen, R. Van-lier, I. Berge et al., Clinical and Immunologic Aspects of Cytomegalovirus Infection in Solid Organ Transplant Recipients, Transplantation, vol.79, issue.4, pp.381-387, 2005.
DOI : 10.1097/01.TP.0000148239.00384.F0

J. Fishman, V. Emery, R. Freeman, M. Pascual, L. Rostaing et al., Cytomegalovirus in transplantation ? challenging the status quo, Cytomegalovirus in transplantation challenging the status quo, pp.149-58, 2007.
DOI : 10.1111/j.1600-6143.2004.00571.x

T. Jones, S. Lee, S. Johann, V. Razinkov, R. Visalli et al., Specific Inhibition of Human Cytomegalovirus Glycoprotein B-Mediated Fusion by a Novel Thiourea Small Molecule, Journal of Virology, vol.78, issue.3, pp.1289-1300, 2004.
DOI : 10.1128/JVI.78.3.1289-1300.2004

K. Biron, R. Harvey, S. Chamberlain, S. Good, A. Smith et al., Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole L-Riboside with a Unique Mode of Action, Antimicrobial Agents and Chemotherapy, vol.46, issue.8, 2002.
DOI : 10.1128/AAC.46.8.2365-2372.2002

S. Ohlmann, B. Lioure, N. Cojean, P. Lutz, F. Uettwiller et al., Drug-resistant cytomegalovirus in transplant recipients: a French cohort study, J Antimicrob Chemother, vol.65, pp.2628-2640, 2010.

J. Lalezari, J. Aberg, L. Wang, M. Wire, R. Miner et al., Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding, Antimicrobial Agents and Chemotherapy, vol.46, issue.9, pp.2969-2976, 2002.
DOI : 10.1128/AAC.46.9.2969-2976.2002

L. Wang, R. Peck, Y. Yin, J. Allanson, R. Wiggs et al., Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects, Antimicrobial Agents and Chemotherapy, vol.47, issue.4, pp.1334-1342, 2003.
DOI : 10.1128/AAC.47.4.1334-1342.2003

F. Marty, P. Ljungman, G. Papanicolaou, D. Winston, R. Chemaly et al., Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial, The Lancet Infectious Diseases, vol.11, issue.4, pp.284-292, 2011.
DOI : 10.1016/S1473-3099(11)70024-X

T. Efferth, M. Marschall, X. Wang, S. Huong, I. Hauber et al., Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses, Journal of Molecular Medicine, vol.80, issue.4, pp.233-242, 2001.
DOI : 10.1007/s00109-001-0300-8

R. Sellar, K. Ward, K. Thomson, and K. Peggs, Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT, Bone Marrow Transplantation, vol.47, issue.11, pp.1482-1483, 2012.
DOI : 10.1016/S0140-6736(03)15162-8

A. Schreiber, G. Härter, A. Schubert, D. Bunjes, T. Mertens et al., Antiviral treatment of cytomegalovirus infection and resistant strains, Expert Opinion on Pharmacotherapy, vol.4, issue.2, pp.191-209, 2009.
DOI : 10.1159/000053979

G. Champier, A. Couvreux, S. Hantz, A. Rametti, M. Mazeron et al., Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity, Antivir Ther, vol.13, pp.643-654, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00406828

T. Goldner, G. Hewlett, N. Ettischer, H. Ruebsamen-schaeff, H. Zimmermann et al., The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase, Journal of Virology, vol.85, issue.20, pp.10884-10893, 2011.
DOI : 10.1128/JVI.05265-11

R. Chemaly, A. Ullmann, S. Stoelben, M. Richard, M. Bornhäuser et al., Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation, New England Journal of Medicine, vol.370, issue.19, pp.1781-1789, 2014.
DOI : 10.1056/NEJMoa1309533

W. Painter, A. Robertson, L. Trost, S. Godkin, B. Lampert et al., First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses, Antimicrobial Agents and Chemotherapy, vol.56, issue.5, 2012.
DOI : 10.1128/AAC.05983-11

K. Hostetler, Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art, Antiviral Research, vol.82, issue.2, pp.84-98, 2009.
DOI : 10.1016/j.antiviral.2009.01.005

K. Aldern, S. Ciesla, K. Winegarden, and K. Hostetler, Increased Antiviral Activity of 1-O-Hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 Human Lung Fibroblasts Is Explained by Unique Cellular Uptake and Metabolism, Molecular Pharmacology, vol.63, issue.3, pp.678-681, 2003.
DOI : 10.1124/mol.63.3.678

L. Dropulic and J. Cohen, Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections, Clinical Pharmacology & Therapeutics, vol.5, issue.5, pp.610-619, 2010.
DOI : 10.1038/clpt.2010.178

S. Williams-aziz, C. Hartline, E. Harden, S. Daily, M. Prichard et al., Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro, Antimicrobial Agents and Chemotherapy, vol.49, issue.9, 2005.
DOI : 10.1128/AAC.49.9.3724-3733.2005

J. Beadle, C. Hartline, K. Aldern, N. Rodriguez, E. Harden et al., Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro, Antimicrobial Agents and Chemotherapy, vol.46, issue.8, pp.2381-2386, 2002.
DOI : 10.1128/AAC.46.8.2381-2386.2002

T. Sekine, S. Cha, and H. Endou, The multispecific organic anion transporter (OAT) family, Pfl??gers Archiv - European Journal of Physiology, vol.440, issue.3, pp.337-50, 2000.
DOI : 10.1007/s004240000297

B. Hagenbuch and C. Gui, Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family, Xenobiotica, vol.280, issue.41, pp.778-801, 2008.
DOI : 10.1053/jhep.2002.34133

H. Koepsell, K. Lips, and C. Volk, Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications, Pharmaceutical Research, vol.61, issue.7, pp.1227-51, 2007.
DOI : 10.1007/s11095-007-9254-z

M. Ritzel, A. Ng, S. Yao, K. Graham, S. Loewen et al., Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib), Molecular Membrane Biology, vol.18, issue.1, pp.65-72, 2001.
DOI : 10.1080/09687680010026313

M. Otsuka, T. Matsumoto, R. Morimoto, S. Arioka, H. Omote et al., A human transporter protein that mediates the final excretion step for toxic organic cations, Proceedings of the National Academy of Sciences, vol.102, issue.50, pp.17923-17931, 2005.
DOI : 10.1073/pnas.0506483102

A. Nies, H. Koepsell, K. Damme, and M. Schwab, Organic Cation Transporters (OCTs, MATEs), In Vitro and In Vivo Evidence for the Importance in Drug Therapy, Handb Exp Pharmacol, pp.105-67
DOI : 10.1007/978-3-642-14541-4_3

P. Roepe, The P-Glycoprotein Efflux Pump: How Does it Transport Drugs?, The Journal of Membrane Biology, vol.272, issue.1, pp.71-74, 1998.
DOI : 10.1007/s002329900448

K. Köck, M. Grube, G. Jedlitschky, L. Oevermann, W. Siegmund et al., Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy, 2007.

W. Mahony, B. Domin, and T. Zimmerman, Ganciclovir permeation of the human erythrocyte membrane, Biochemical Pharmacology, vol.41, issue.2, pp.263-271, 1991.
DOI : 10.1016/0006-2952(91)90485-N

DOI : 10.1097/00007890-199812270-00019

D. Winston, D. Wirin, A. Shaked, and R. Busuttil, Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients, The Lancet, vol.346, issue.8967, pp.69-74, 1995.
DOI : 10.1016/S0140-6736(95)92110-9

C. Fletcher and H. Balfour, Evaluation of ganciclovir for cytomegalovirus disease, DICP Ann Pharmacother, vol.23, pp.5-12, 1989.

C. Fletcher, R. Sawchuk, B. Chinnock, P. De-miranda, and H. Balfour, Human pharmacokinetics of the antiviral drug DHPG, Clinical Pharmacology and Therapeutics, vol.40, issue.3, pp.281-286, 1986.
DOI : 10.1038/clpt.1986.177

S. Majumdar, S. Macha, D. Pal, and A. Mitra, Mechanism of ganciclovir uptake by rabbit retina and human retinal pigmented epithelium cell line ARPE-19, Current Eye Research, vol.17, issue.2, pp.127-136, 2004.
DOI : 10.1023/A:1015890516119

G. Pacifici, Transfer of antivirals across the human placenta, Early Human Development, vol.81, issue.8, pp.647-654, 2005.
DOI : 10.1016/j.earlhumdev.2005.02.002

L. Gilstrap, R. Bawdon, S. Roberts, and S. Sobhi, The transfer of the nucleoside analog ganciclovir across the perfused human placenta, American Journal of Obstetrics and Gynecology, vol.170, issue.4, pp.967-972, 1994.
DOI : 10.1016/S0002-9378(94)70089-3

K. Kotrych, T. Sulikowski, L. Doma?ski, M. Bia?ecka, and M. Dro?dzik, Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population, Pharmacol Rep PR, vol.59, pp.199-205, 2007.

M. Paloncýová, R. Devane, B. Murch, K. Berka, and M. Otyepka, Amphiphilic Drug-Like Molecules Accumulate in a Membrane below the Head Group Region, The Journal of Physical Chemistry B, vol.118, issue.4, pp.1030-1039, 2014.
DOI : 10.1021/jp4112052

K. Matsumoto, A. Shigemi, K. Ikawa, N. Kanazawa, Y. Fujisaki et al., Risk Factors for Ganciclovir-Induced Thrombocytopenia and Leukopenia, Biological and Pharmaceutical Bulletin, vol.38, issue.2, pp.235-238, 2015.
DOI : 10.1248/bpb.b14-00588

T. Merigan, D. Renlund, S. Keay, M. Bristow, V. Starnes et al., A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation, New England Journal of Medicine, vol.326, issue.18, pp.1182-1186, 1992.
DOI : 10.1056/NEJM199204303261803

E. Gane, F. Saliba, G. Valdecasas, O. Grady, J. Pescovitz et al., Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients, The Lancet, vol.350, issue.9093, pp.1729-1733, 1997.
DOI : 10.1016/S0140-6736(97)05535-9

J. Mcgavin and K. Goa, Ganciclovir, Drugs, vol.168, issue.7, pp.1153-1183, 2001.
DOI : 10.2165/00003495-200161080-00016

N. Perrottet, C. Csajka, M. Pascual, O. Manuel, F. Lamoth et al., Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir, Antimicrobial Agents and Chemotherapy, vol.53, issue.7, pp.3017-3023, 2009.
DOI : 10.1128/AAC.00836-08

Z. Chen, K. Lee, and G. Kruh, Transport of Cyclic Nucleotides and Estradiol 17-??-D-Glucuronide by Multidrug Resistance Protein 4: RESISTANCE TO 6-MERCAPTOPURINE AND 6-THIOGUANINE, Journal of Biological Chemistry, vol.276, issue.36, pp.33747-33754, 2001.
DOI : 10.1074/jbc.M104833200

J. Schuetz, M. Connelly, D. Sun, S. Paibir, P. Flynn et al., MRP4: A previously unidentified factor in resistance to nucleosidebased antiviral drugs, Nature Medicine, vol.5, issue.9, pp.1048-1051, 1999.
DOI : 10.1038/12487

P. Anderson, J. Lamba, C. Aquilante, E. Schuetz, and C. Fletcher, Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.4, pp.441-449, 1999.
DOI : 10.1097/01.qai.0000225013.53568.69

J. Kiser, C. Aquilante, P. Anderson, T. King, M. Carten et al., Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.47, issue.3, pp.298-303, 1999.
DOI : 10.1097/QAI.0b013e31815e7478

M. Ansari, G. Sauty, M. Labuda, V. Gagné, C. Laverdière et al., Polymorphisms in multidrug resistance-associated protein gene 4, 2009.

U. Gradhand, T. Lang, E. Schaeffeler, H. Glaeser, H. Tegude et al., Variability in human hepatic MRP4 expression: influence of cholestasis and genotype, The Pharmacogenomics Journal, vol.47, issue.1, pp.42-52, 2007.
DOI : 10.1038/sj.tpj.6500451

E. Woodahl, M. Crouthamel, T. Bui, D. Shen, and R. Ho, MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents, Cancer Chemotherapy and Pharmacology, vol.18, issue.1, pp.183-188, 2009.
DOI : 10.1007/s00280-008-0906-4

H. Gréen, P. Söderkvist, P. Rosenberg, G. Horvath, and C. Peterson, ABCB1 G1199A Polymorphism and Ovarian Cancer Response to Paclitaxel, Journal of Pharmaceutical Sciences, vol.97, issue.6, pp.2045-2048, 2008.
DOI : 10.1002/jps.21169

H. Gréen, I. Falk, K. Lotfi, E. Paul, M. Hermansson et al., Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype, The Pharmacogenomics Journal, vol.65, issue.2, pp.111-118, 2012.
DOI : 10.1038/tpj.2010.79

M. Tamura, M. Kondo, M. Horio, M. Ando, H. Saito et al., Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity, Nagoya J Med Sci, vol.74, pp.133-140, 2012.

X. Chen, D. Chen, S. Yang, R. Ma, Y. Pan et al., Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced nonsmall-cell lung cancer patients, Cancer Cell Int, vol.15, 2015.

P. Zhu, Q. Zhu, Y. Zhang, X. Ma, Z. Li et al., ABCB1 Variation and Treatment Response in AIDS Patients: Initial Results of the Henan Cohort, PLoS ONE, vol.19, issue.1, p.55197, 2013.
DOI : 10.1371/journal.pone.0055197.s002

E. Gardner, H. Burger, R. Van-schaik, A. Van-oosterom, E. De-bruijn et al., Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib, Clinical Pharmacology & Therapeutics, vol.80, issue.2, pp.192-201, 2006.
DOI : 10.1016/j.clpt.2006.05.003

M. Koren-michowitz, Z. Buzaglo, E. Ribakovsky, M. Schwarz, I. Pessach et al., OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients, European Journal of Haematology, vol.83, issue.4, pp.283-288, 2014.
DOI : 10.1111/ejh.12235

S. Yee, J. Shima, S. Hesselson, L. Nguyen, D. Val et al., Identification and Characterization of Proximal Promoter Polymorphisms in the Human Concentrative Nucleoside Transporter 2 (SLC28A2), Journal of Pharmacology and Experimental Therapeutics, vol.328, issue.3, pp.699-707, 2009.
DOI : 10.1124/jpet.108.147207

A. Doehring, W. Hofmann, C. Schlecker, S. Zeuzem, C. Sarrazin et al., Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy, Pharmacogenetics and Genomics, vol.21, issue.5, pp.289-296, 2011.
DOI : 10.1097/FPC.0b013e32834412e7

Y. Suzuki, M. Homma, M. Abei, I. Hyodo, and Y. Kohda, Impact of Solute Carrier Family 29 Member 1 (SLC29A1) Single Nucleotide Polymorphisms on mRNA Expression in Peripheral Blood Mononuclear Cells, Biological and Pharmaceutical Bulletin, vol.36, pp.144-146, 2013.
DOI : 10.1248/bpb.b12-00809

I. Cascorbi, P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations, Handb Exp Pharmacol, pp.261-283, 2011.
DOI : 10.1007/978-3-642-14541-4_6

S. Park, W. Lee, J. Lee, and I. Kim, Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase, Cancer Letters, vol.261, issue.2, pp.205-214, 2008.
DOI : 10.1016/j.canlet.2007.11.011

L. Oevermann, J. Scheitz, K. Starke, K. Köck, T. Kiefer et al., Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs, International Journal of Cancer, vol.89, issue.Part 2, pp.2303-2311, 2009.
DOI : 10.1002/ijc.24207

X. Wang, T. Furukawa, T. Nitanda, M. Okamoto, Y. Sugimoto et al., Breast Cancer Resistance Protein (BCRP/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors, Molecular Pharmacology, vol.63, issue.1, pp.65-72, 2003.
DOI : 10.1124/mol.63.1.65

M. Takeda, S. Khamdang, S. Narikawa, H. Kimura, Y. Kobayashi et al., Human Organic Anion Transporters and Human Organic Cation Transporters Mediate Renal Antiviral Transport, Journal of Pharmacology and Experimental Therapeutics, vol.300, issue.3, pp.918-924, 2002.
DOI : 10.1124/jpet.300.3.918

R. Owen, I. Badagnani, and K. Giacomini, Molecular Determinants of Specificity for Synthetic Nucleoside Analogs in the Concentrative Nucleoside Transporter, CNT2, Journal of Biological Chemistry, vol.281, issue.36, pp.26675-26682, 2006.
DOI : 10.1074/jbc.M513421200

M. Redell, A. Tsimelzon, S. Hilsenbeck, and D. Tweardy, Conditional overexpression of Stat3?? in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern, Journal of Leukocyte Biology, vol.82, issue.4, pp.975-985, 2007.
DOI : 10.1189/jlb.1206766

R. Leary, R. Jelliffe, A. Schumitzky, and M. Van-guilder, An adaptive grid nonparametric approach to pharmacokinetic and dynamic (PK/PD) population models, Fourteenth Ieee Symposium on Computer-Based Medical Systems, Proceedings. Ieee Computer Soc, pp.389-394, 2001.

T. Tatarinova, M. Neely, J. Bartroff, M. Van-guilder, W. Yamada et al., Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian, Journal of Pharmacokinetics and Pharmacodynamics, vol.21, issue.4, pp.189-199, 2013.
DOI : 10.1007/s10928-013-9302-8

H. Akaike, Information Theory and an Extension of the Maximum Likelihood Principle, pp.199-213, 1998.